Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ginkgo Bioworks reports strong Q4 earnings, eyes biopharma growth

Ginkgo Bioworks reports strong financial performance and strategic growth in Q4 2022, focusing on downstream value share and biosecurity leadership.
While facing challenges with negative EBITDA, the company aims to drive efficiency, expand biosecurity initiatives, and capitalize on opportunities in biopharma and API manufacturing.
With a solid financial foundation, Ginkgo is well-positioned to leverage its expertise in programming cells and proprietary protein sequences for future growth and market expansion.

Ginkgo Bioworks reports strong Q1 growth and eyes global expansion

Ginkgo Bioworks showcased strong performance in Cell Engineering and Biosecurity revenue, emphasizing platform improvement and strategic partnerships.
While facing challenges in enterprise sales and operating expenses, the company is well-positioned for growth through international biosecurity expansion and biopharma focus.
Opportunities lie in global biosecurity initiatives, biopharma sales pipeline, and persistent monitoring programs, signaling a promising future for Ginkgo.

Ginkgo Bioworks posts robust Q2 results, eyes revenue diversification

Ginkgo Bioworks reported strong growth in revenue and active programs, with a focus on operational efficiencies and customer relationships.
Transitioning to success-based pricing models and task-specific data training positions the company for revenue diversification and enhanced customer value.
While facing market challenges and funding constraints, Ginkgo is strategically expanding its offerings and driving towards profitability through operational enhancements.

Ginkgo Bioworks reports strong Q3 performance and biosecurity opportunities

Ginkgo Bioworks reports strong performance with revenue growth and increased active programs.
The company's strengths lie in AI progress, diverse customer base, and biosecurity applications.
Challenges include deal timing, competitive positioning, and managing operational expenses.
Opportunities include tech licensing deals, AI-driven efficiency, and synergies between biosecurity and cell engineering.

Ginkgo Bioworks navigates revenue challenges with strategic growth initiatives

Ginkgo Bioworks faces revenue challenges from program dynamics but is strategically positioned for growth through R&D investments and partnerships.
The company's focus on innovation, efficiency, and biosecurity infrastructure underscores its commitment to leading in biotech R&D.
Opportunities in expanding partnerships, enhancing automation technology, and standardizing interfaces signal a promising path for Ginkgo's future growth.
Despite short-term revenue setbacks, Ginkgo's strategic initiatives and industry positioning bode well for long-term success and market leadership.

Ginkgo Bioworks targets EBITDA breakeven by 2026 amid revenue challenges

Ginkgo Bioworks is navigating challenges in revenue growth while focusing on cost reductions and operational efficiency to achieve EBITDA breakeven by 2026.
The company's strategic shift towards biopharma and bioAg sectors showcases flexibility and growth potential in serving large companies with research budgets.
Introduction of 'Lab Data as a Service' and focus on streamlining workflows present opportunities for scalability and revenue enhancement.
Despite challenges in revenue outlook and restructuring efforts, Ginkgo remains committed to operational success and financial sustainability.

Ginkgo Bioworks advances cost-saving goals amidst revenue challenges

Ginkgo Bioworks progresses towards financial targets amidst revenue challenges and aggressive cost-saving measures.
Strategic focus on automation, biosecurity, and revenue diversification positions the company for future growth.
Challenges include revenue decline, employee impact from layoffs, and balancing cost reduction with innovation.
Opportunities lie in new revenue streams, margin accretive initiatives, and market differentiation through mission-driven approach.

Ginkgo Bioworks reports mixed Q3 results, focuses on growth strategies

Ginkgo Bioworks showed strength in cost-cutting, revenue generation, and strategic focus, despite a negative adjusted EBITDA.
Challenges include financial pressures, margin concerns, and potential risks in resource utilization and funding stability.
Opportunities lie in new offerings, AI capabilities, market expansion, and revenue scale for improved profitability.
Management's emphasis on cost reduction, revenue growth, and innovation positions the company for long-term success and sustainability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW ORLEANS , Sept. 20, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C.

ZYMERGEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Zymergen - ZY

Intellia Therapeutics

Teladoc

These stocks aren't for the faint of heart.

Cathie Wood Is Loading Up on These 3 Stocks: Should You?

It's possible the Oracle of Omaha would want to get on board for this stock, but not for at least a few years.

Could Warren Buffett and Cathie Wood Agree on Buying This Growth Stock?

Ginkgo Bioworks is, along with Amyris, the leader in synthetic biology. A one-of-a-kind business model, solid technology and platform, a wide range of markets and applications, compounding potential, a reasonable valuation, and minimal cash burn, make Ginkgo attractive.

Ginkgo Bioworks: May The Ginkgo King Grow

Ginkgo Bioworks is expanding so quickly that it could slow down a lot and still two times.

This Cathie Wood Stock Could Double Within 3 Years -- Here's How

BOSTON , Sept. 12, 2022 /PRNewswire/ -- The White House today announced that President Biden intends to appoint Renee Wegrzyn, PhD, as the first Director of the Advanced Research Projects Agency for Health ( ARPA-H ).

Renee Wegrzyn Slated to Lead New Advanced Research Projects Agency for Health

Bird Rides

FuboTV

IMARA

Lufax Holding

PLBY Group

Party City Holdco

Sorrento Therapeutics Inc

Tellurian

Vroom

Penny stocks to watch today with unusual options action. The post 10 Top Penny Stocks With Unusual Options Activity This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks With Unusual Options Activity This Week

BOSTON , Sept. 1, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced that Behzad Mahdavi, Ph.D.

Ginkgo Bioworks Appoints Dr. Behzad Mahdavi as Senior Vice President of Biopharma Manufacturing & Life Science Tools

Boston-based Ginkgo Bioworks (NYSE: DNA ) is a biotechnology company that's advancing a platform for cell programming. Reportedly, famous ARK Invest fund manager Cathie Wood bought a large stake in DNA stock not long ago.

Don't Jump Into the Deepening Financial Hole with Ginkgo Bioworks

Amyris

Lovesac Company

The experts say these stocks aren't getting half the appreciation that they deserve.

3 Stocks That Can Double Your Money According to Wall Street

Zymergen

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Zymergen Inc. (NasdaqGS: ZY) to Ginkgo Bioworks Holdings, Inc. (NYSE: DNA). Under the terms of the proposed transaction, shareholders of Zymergen will receive a fixed exchange ratio of 0.9179 Ginkgo shares for each share of Zymergen that they own. KSF is seeking to determine whether this consideration and the

ZYMERGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Zymergen - ZY

ChromaDex

Health and wellness industry veteran will lead the company to scale sustainable bioactives using plant cell technology instead of agriculture                                                      BOSTON , Aug. 24, 2022 /PRNewswire/ -- Ayana Bio, the plant cell technology company making sustainable bioactives for consumer products, today announced the appointment of Frank Jaksch as the company's chief executive officer. Jaksch founded, was the longtime CEO and presently serves as Board Chair of health and wellness company ChromaDex, manufacturer of popular NAD product, Tru Niagen (Nasdaq: CDXC).

Ayana Bio Announces Appointment of Frank Jaksch as Chief Executive Officer

DraftKings

Zoom Video

Beam Therapeutics

CRISPR Therapeutics

This article is excerpted from Tom Yeung's Profit & Protection newsletter dated Aug. 16, 2022. To make sure you don't miss any of Tom's picks, subscribe to his mailing list here.

5 Cathie Wood Stocks Signaling “The Bear Market Is Over”

Cathie Wood's infatuation with Ginkgo Bioworks (NYSE: DNA ) stock continued this week. The ARK Invest fund manager purchased an additional 1.13 million shares of the gene editing company on Thursday, adding to her already sizable holdings of DNA stock.

Cathie Wood Is Doubling Down on Ginkgo Bioworks (DNA) Stock

Transaction is expected to bolster Ginkgo's growing biosecurity platform and provide expanded epidemic tracking, modeling, and forecasting offerings to public health leaders and communities BOSTON , Aug. 19, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the purchase of certain epidemiological data infrastructure assets from Baktus, Inc., a Delaware-based public benefit corporation. Under the terms of the deal, Ginkgo will assume ownership of proprietary datasets, modeling and analytic tools, and a software platform with the capabilities to track, model, and forecast epidemics and associated risks and impacts.

Ginkgo Bioworks Announces Strategic Purchase of Epidemiological Data Infrastructure Assets

Investors warmly greeted the company's latest quarterly earnings report.

Why Ginkgo Bioworks Stock Blasted 7% Higher Today

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Anna Marie Wagner – Senior Vice President-Corporate Development Jason Kelly – Co-Founder and Chief Executive Officer Mark Dmytruk – Chief Financial Officer Conference Call Participants Matt Sykes – Goldman Sachs Matt Larew – William Blair Tejas Savant – Morgan Stanley Steve Mah – Cowen Rahul Sarugaser – Raymond James Vivian Bais – BTIG Anna Marie Wagner Good afternoon. This is Anna Marie Wagner, SVP of Corporate Development at Ginkgo Bioworks.

Ginkgo Bioworks Holdings, Inc. (DNA) CEO Jason Kelly on Q2 2022 Results - Earnings Call Transcript

$145 million of Total revenue in Q2 2022, representing 231% growth over Q2 2021 13 new Cell Programs added in Q2 2022, representing 86% growth over Q2 2021 Pending acquisitions of Zymergen and Bayer's West Sacramento agricultural biologicals capabilities expected to enable new growth opportunities in the coming years Approximately $1.4 billion cash balance provides continued multi-year runway as Ginkgo drives towards profitability BOSTON, Aug. 15, 2022 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo"), the leading horizontal platform for cell programming, today announced its results for the second quarter ended June 30, 2022. The update, including a webcast slide presentation with additional details on the second quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.

Ginkgo Bioworks Reports Second Quarter 2022 Financial Results

Synlogic

SYNB2081 is the second clinical drug candidate developed through the partnership between Ginkgo and Synlogic CAMBRIDGE, Mass. and BOSTON , Aug. 11, 2022 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced a new drug candidate for the treatment of gout developed in partnership with Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming.

Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks

Collaboration aims to leverage innovative biosecurity capabilities to promote global health security and accelerate the development of the regional bioeconomy BOSTON and KIGALI, Rwanda , Aug. 11, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and the Rwanda Development Board ("RDB"), representing the government of the Republic of Rwanda, today announced that they have entered into a Memorandum of Understanding ("MOU") with the intent of developing and implementing new biosecurity capabilities in Rwanda. The initial goal of the planned partnership is to support Rwanda's public health institutions as they work to address biosecurity challenges in the region.

Ginkgo Bioworks and the Rwanda Development Board Announce Plans to Develop and Implement New Biosecurity Capabilities in Rwanda

Alignment Healthcare

Desktop Metal

Gentex

Planet Fitness

The RealReal

Shoals Technologies Group

SoFi Technologies

UnitedHealth Group

Upstart Holdings

This article is excerpted from Tom Yeung's Profit & Protection newsletter dated Aug. 9, 2022. To make sure you don't miss any of Tom's picks, subscribe to his mailing list here.

10 Stocks That Could Rise 10x (Safely)

There is a developing animosity towards manufactured nitrogen fertilizers amongst the ruling classes. Many well-known politicians are extolling the virtues of avoiding farmed meat products.

Ginkgo Bioworks: Time To Buy

Presentation and Q&A session scheduled for post-market on Monday, August 15, 2022 BOSTON , Aug. 8, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that it plans to host a presentation and Q&A session reviewing business performance for the second quarter ended June 30, 2022, on Monday, August 15, 2022, beginning at 4:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.

Ginkgo Bioworks Announces Date of Second Quarter 2022 Results Presentation

Now's a great time to invest in companies with the potential to grow significantly in the long term.

Should You Really Be Buying Beaten-Down Growth Stocks Right Now?

Beaten down from its highs late last year, cell engineering company Ginkgo Bioworks now looks primed to divide and conquer.

News for Ginkgo Bioworks Holdings Stock (DNA)